The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Hepatitis C patients can add ACTILON to their list of treatments to keep an eye on. After positive preliminary testing, the USFDA granted Fast Track status to this drug designed to sustain immune responses in chronically infected liver patients.
Continue reading »New combinations of therapies are making significant progress in improving hepatitis symptoms. Learn more about these progressive treatments.
Continue reading »The recent discovery that the Hepatitis C virus needs a small part of RNA found only in the liver to replicate itself has sparked new treatment approaches. If researchers can determine whether lowering the amount of this RNA decreases viral load without adversely affecting the liver we may see a promising breakthrough.
Continue reading »By overcoming the difficulties of culturing live HCV, scientists are now capable of studying the virus more closely. We anticipate this progress will open the door to hepatitis C treatment and prevention.
Continue reading »Biologists at Florida State University have recently produced a study illuminating the replication and mutation of the Hepatitis C virus. This kind of progress represents a giant leap forward in tracking this persistent virus, which likely means more accurate and efficient therapy will be coming soon.
Continue reading »Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development.
Continue reading »The start of the New Year was accompanied by the European Patent Office granting a patent for a rapid HCV test. Now that the technology is here, let's hope the test proves accurate, with high levels of selectivity and specificity.
Continue reading »While GlobeImmune's therapeutic vaccine for Hepatitis C is only in Phase Ib of clinical trials, their focus on immunity to the Hepatitis C virus is fascinating. GI-5005 is based on tarmogens being potent activators of antigen-specific immune responses against disease.
Continue reading »As you may recall we've been saying VX-950 is the revolutionary new therapy to watch for HCV. Now it looks like the FDA agrees this treatment is quite promising and deserving of faster approval than a lesser worthy approach. Another reason they are doing this is they know current therapy options are less than ideal.
Continue reading »It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are... View Article
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
